Agents at the Peak of US FDA Approval for the Treatment of Alzheimer’s Disease

ABSTRACT

Where Alzheimer’s disease (AD) is becoming a global health issue, the present anti-AD medications have also been exposed to produce only symptomatic outcomes. The pathological factors, like neuronal transmission impairment, amyloidal-tau constituents, oxidative damage, neuro-inflammation, synaptic dysfunction, infectious agents, and impairment of gut microbiota and vitamins’ levels; all favor the disease’s progression and sustainability. The researchers have investigated several drugable molecules against these factors; however, no treatment could have been discovered yet to prevent the disease’s progression rather than anti-amyloidal antibodies. After a comprehensive review of the literature and the clinical registry (clinicaltrials.gov), the authors of this manuscript have explored drug molecules that are under phase-3 of clinical trials and at the peak of getting approval for the management of AD. The inclusion and exclusion criteria for clinical trials were decided by considering the basis of a drug’s approval. We included only the clinical trials were found in stages of Enrolling-by-Invitation, Recruiting, Not Recruiting (But active), and Not Recruiting (Not active) while excluding Completed, Terminated, Suspended, Withdrawn, or the trials of Unknown Status. We have found many potent drug molecules reached the clinical trials in phase-3 that could be futuristic anti-AD agents. This review article aims to provide an update on the prospective potential anti-AD medicines and to reveal the therapeutic targets of great significance for designing further a possible drug development strategy against AD pathology.

KEYWORDS:

• Alzheimer’s disease (AD)
• clinical trials
• phase-3 trials
• drug development pipeline
• US FDA approval

View correction statement:

Correction

Acknowledgments

The authors are thankful to all the affiliated institutions for providing the internet and library facilities to carry out the literature regarding the present work. Additionally, the corresponding author appreciates the suggestions recommended for the improvements of the manuscript from Prof. Neeraj Mahindroo (MIT WPU, India) and Dr. Varun Jaiswal (Gachon University, South Korea).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Correction Statement

This article was originally published with errors, which have now been corrected in the online version. Please see Correction 10.1080/01616412.2024.2310926